期刊
BRITISH JOURNAL OF HAEMATOLOGY
卷 186, 期 4, 页码 561-564出版社
WILEY
DOI: 10.1111/bjh.15968
关键词
essential thrombocythaemia; interferon; thrombosis; therapy; cytoreduction; myeloproliferative disorder
类别
Standard first-line therapy choice for essential thrombocythaemia (ET) requiring cytoreduction, supported by randomized trials, is low-dose aspirin with hydroxycarbamide, but the role of recombinant interferon-alfa (IFN alpha)-2a/2b and pegylated (PEG)-IFN-alpha-2a/2b is increasingly highlighted. Longer-term outcome data, however, remains somewhat scarce, particularly in the 'real world'. We hereby report on a large, well-annotated cohort of ET patients from a single referral centre undergoing therapy with either IFN alpha or (PEG)-IFN-alpha-2a/2b and demonstrate high rates of complete haematological responses, good tolerability and safety, low rates of thromboembolic events in compliant patients and confirm feasibility of long-term therapy in a significant proportion of patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据